Care Home Valuation UK 2026: CQC and Welltower

The UK care home M&A market in May 2026 sits at one of the most unusual inflection points in its history. Two forces are reshaping how independent operators are valued: the CMA's phase 1 decision on 7 May 2026 against Welltower's £5.2 billion acquisition of Barchester Healthcare and parallel £1.2 billion acquisition of HC-One, and the ongoing transition of the Care Quality Commission's Single Assessment Framework following the Better Regulation, Better Care consultation that closed in December 2025.

For owners of independent care homes valued between £1 million and £30 million, the consequences are immediate. Buyer competition is intensifying, regulatory rating outcomes have become the single largest determinant of multiple within a tight band, and the per-bed metric that has anchored UK care home valuations for two decades is being recalibrated against new operational and capital benchmarks. This guide sets out how UK care homes are valued in 2026, the current EBITDA multiple range, the named buyer landscape, the value drivers that materially move price, and the diligence items every seller must prepare. If you operate in this sector, our care home advisory team maintains live transaction comparables and CQC-rating-banded multiple data across every UK region.

The 2026 UK care home valuation framework

UK care home valuations in 2026 are constructed using three complementary methods, and serious buyers cross-check all three before submitting an offer.

Method one: EBITDA multiple. The dominant valuation method for trading businesses. Sustainable adjusted EBITDA is multiplied by a market-derived multiple that reflects CQC rating, occupancy, fee mix, location, freehold status and operational quality. Christie & Co data from 2024 transactions confirmed a range of 5x to 12x EBITDA across completed UK deals. UHY Hacker Young's published 2024 guidance places typical UK multiples in a 4x to 10x range, with leased homes carrying a minimum 2x reduction relative to freehold equivalents. Through 2025 and into 2026 the range has compressed slightly toward the upper end for Good and Outstanding rated freehold homes as PE-backed and REIT capital has intensified competition for premium assets.

Method two: price per bed. The traditional sense-check metric. Christie & Co reported per-bed transaction outcomes between £30,000 and £360,000 in 2024 across the full UK market. The wide spread reflects extreme variance in CQC rating, property quality, location, freehold status and fee mix. For a 40-bed Good-rated freehold home in the South East with strong self-funder share, expect £120,000 to £180,000 per bed as a current benchmark. For a Requires Improvement rated home with majority local authority funding, £40,000 to £70,000 per bed is more typical.

Method three: maintainable turnover multiple. Used primarily as a cross-check. UHY Hacker Young reported live UK listings ranging from 1.23x to 2.22x turnover. For most independent operators the EBITDA multiple and per-bed methods carry more weight in the final negotiation, but the turnover multiple is useful for sense-checking offers that look outside the expected band.

The single most important practical observation: in care home transactions the headline multiple matters less than the working capital adjustment, net debt definition, property valuation methodology and any deferred consideration mechanic. Our buy-side advisory team routinely sees cash at completion vary by 15% to 25% versus the headline enterprise value purely on these mechanics. Owners focused only on the multiple typically leave material value behind. Similar dynamics affect veterinary practice valuations and dental practice sales, where corporate buyer SPAs use almost identical structural levers.

The CQC rating premium and its 2026 evolution

The Care Quality Commission's rating system remains the single largest external factor in care home valuation. Under the Single Assessment Framework the four ratings are Outstanding, Good, Requires Improvement and Inadequate. The January 2026 CQC rating distribution published by Fulcrum Care Consulting covering 181 inspection reports was: 7 Outstanding (3.9%), 87 Good (48.1%), 72 Requires Improvement (39.8%), 15 Inadequate (8.3%).

The valuation premium for higher ratings is well established in market data:

Outstanding rated homes command a roughly 15% to 30% premium on multiple over a comparable Good rated home, primarily because corporate buyers price them as platform-grade assets that can underwrite continued strong cash generation and support borrowing capacity. The scarcity (only around 4% of inspected homes achieve Outstanding) creates persistent buyer competition.

Good rated homes sit at the market clearing multiple for most transactions. Buyer interest from corporates, PE-backed groups and regional operators is strong across the rating.

Requires Improvement rated homes typically trade at a 25% to 40% discount to comparable Good rated homes, with the discount narrowing if the operator has a credible improvement plan and recent positive inspection trend. Buyers also build in significant working capital buffers in the SPA.

Inadequate rated homes are essentially uninvestable for institutional capital. Transactions typically occur at distressed valuations to specialist turnaround operators, with deal structures heavily weighted toward earn-outs contingent on rating recovery.

The 2026 dimension that owners must understand is the regulatory uncertainty introduced by the Better Regulation, Better Care consultation. The CQC's consultation, which closed in December 2025 following criticism from Dame Penny Dash's review and the Care Providers Alliance, proposed three significant changes:

1. Sector-specific frameworks for different service types (residential care, homecare, nursing)
2. Reintroducing supporting questions similar to the old Key Lines of Enquiry
3. Moving away from arithmetic scoring of the 34 Quality Statements toward Ratings Characteristics professional judgement

Until the new framework is finalised, the 34 Quality Statements and the four-point scoring methodology remain operative. The practical implication for sellers is significant: in the transition window buyers are scrutinising not just current rating, but the operator's ability to demonstrate sustained quality evidence across all six CQC evidence categories (people's experience, feedback from staff, feedback from partners, observation, processes, outcomes). Operators with structured digital evidence trails are commanding premiums versus equivalent operators reliant on paper-based records.

The Welltower CMA decision: what it means for sellers

On 7 May 2026 the CMA published its phase 1 decision in the merger inquiry into Welltower Inc's acquisitions of care homes managed by Barchester Healthcare, HC-One, Aria Care (including Asprey) and Danforth Care. The transactions, originally announced in October 2025 by Welltower, totalled over £6 billion in aggregate UK consideration with Barchester alone valued at approximately £5.2 billion, equivalent to roughly $6.9 billion, and HC-One at £1.2 billion or $1.6 billion as reported by Skilled Nursing News.

The CMA's phase 1 finding, summarised by Bevan Brittan, concluded that the transactions give rise to a realistic prospect of a substantial lessening of competition in 30 local areas across England and Scotland. The CMA applied a decision rule that competition concerns arise wherever the combined share of bed capacity reaches 35% or higher in a local market, with an additional 5% incremental share threshold applied between 35% and 40%. As detailed in the CMA's phase 1 decision summary, the Mergers will be referred for a phase 2 in-depth investigation unless Welltower and Apex offer acceptable undertakings.

For independent operators the implications are direct.

Forced divestments are likely in concentrated local markets. Welltower is already exploring transferring acquired homes in problem geographies to new operators. This creates a secondary buyer pool of regional operators and capital partners seeking to deploy quickly into well-located, ready-rated assets. Owners in geographies adjacent to the divestiture areas should expect inbound approaches from buyers building scale.

The big-three corporate landscape has effectively become a big-one. Welltower now controls operators behind over 550 UK care homes through Barchester and HC-One combined, as confirmed in LinkedIn coverage of the Welltower announcement. This consolidation creates a structural opportunity for the next tier (Care UK, Maria Mallaband, Avery Healthcare, Anchor) to acquire to defend regional positioning.

REIT capital pricing dynamics are now visible in UK transactions. Welltower's per-home consideration implies UK care home valuations approaching US REIT benchmarks for premium assets. The transactions establish a market reference point that filters down into multiples for independent operators with comparable quality profiles.

The 24-month transaction window between mid-2026 and mid-2028 will likely be the most active in UK care home M&A history. Owners considering exit should be conducting valuation work and CQC evidence audits now to be ready to engage with buyers in H2 2026 and H1 2027.

The named UK care home buyer landscape in 2026

The UK care home buyer universe in May 2026 sits across five tiers.

Tier 1: Mega-corporate (Welltower-owned). Barchester Healthcare and HC-One, jointly controlled by Welltower, dominate the top of the market by bed count. Subject to CMA undertakings these groups will likely continue acquisition activity in non-concentrated geographies. Multiple range for the homes they target: 8x to 12x adjusted EBITDA for Good or Outstanding freehold assets.

Tier 2: National corporate operators. Care UK, Maria Mallaband Care Group, Anchor Hanover, Bupa Care Services, Four Seasons Health Care, and Avery Healthcare. Active acquirers seeking regional scale and quality assets in catchments aligned with their existing portfolio. Multiple range: 7x to 10x for Good freehold assets.

Tier 3: Regional and specialist operators. Around 50 to 80 named operators across the UK with 10-50 home portfolios, often PE-backed or family office funded, competing for bolt-on opportunities. Often the most active in the £3 million to £15 million enterprise value range. Multiple range: 5.5x to 8x for Good freehold homes.

Tier 4: PE platforms and independent sponsors. Sector specialists building consolidation plays, often with healthcare-focused mid-market PE capital. Target enterprise values £5 million to £30 million. Multiple range: 6x to 9x, with structured upside for sellers willing to participate in earn-outs or roll equity.

Tier 5: REITs and capital partners. Welltower being the dominant example, joined by Target Healthcare REIT, Impact Healthcare REIT, Care REIT, Civitas Social Housing. These investors typically partner with an operator and acquire freehold property, often via sale-and-leaseback structures with the operating business retained. Valuation framework is property-led but operating performance underpins lease covenants.

The care home buyer landscape sits within a broader UK healthcare consolidation pattern that also affects dental practice acquisitions and veterinary group roll-ups, with medispa and aesthetics platforms following similar consolidation playbooks. Owners benchmarking offer quality should treat buyer category, not just headline multiple, as a primary determinant of post-completion experience including lock-in, integration intensity and earn-out risk.

The 12 value drivers that buyers actually price in 2026

Sophisticated UK care home buyers in 2026 underwrite the same 12 drivers in every transaction. Treat this as a pre-sale checklist.

1. CQC rating and rating trajectory. Current rating sets the floor; trajectory across recent inspections sets the buyer's confidence in sustained quality.
2. CQC evidence quality across the six categories. Buyers now request structured evidence files. Operators with digital care record systems (eMAR, structured care planning, audit-ready records) command premiums of 0.5x to 1.0x EBITDA over paper-reliant operators.
3. Occupancy rate, sustained over 24 months. Sub-85% occupancy is a material discount driver. Sustained over 92% supports the upper end of multiple.
4. Self-funder share. Higher self-funder share supports higher EBITDA margins and is treated as more defensible against local authority fee compression. Homes above 60% self-funder typically command 1x to 2x premium on multiple.
5. Local authority fee uplift trend. Real-terms fee growth versus inflation in your contracting LAs. Compressed-fee geographies discount valuations.
6. EBITDA margin and run-rate sustainability. Sustainable adjusted EBITDA margins above 22% support upper multiples; below 18% typically caps at mid-range.
7. Freehold versus leasehold structure. Freehold homes command 1.5x to 3.0x premium on multiple over equivalent leased homes. Confirmed in published Christie & Co and UHY guidance.
8. Property condition and Gross Internal Area per resident. Buyers benchmark GIA per resident; homes below 35m2 per resident face material discount.
9. Staffing model, agency exposure and registered manager continuity. Agency dependency above 12% of staff hours is a value drag; recent registered manager turnover triggers diligence flags.
10. Catchment demographics and competitive intensity. Local 75+ population growth, competing home capacity, and the Nuffield Trust's data showing UK care home bed availability has declined 17.7% per 100 75+ population between 2012 and 2023 all support catchment-level premiums.
11. Capex requirements and PPM compliance. Deferred capex is a direct EBITDA-equivalent deduction; buyers price replacement capex into multiple.
12. Regional fee benchmarking. London and the South East support premiums driven by higher self-funder weekly fees. Per carehome.co.uk regional data, London residential care averages £1,548 per week versus £1,112 in the North East.

Why 2026 favours sellers of well-positioned homes

Three structural forces are pushing UK care home valuations higher for well-positioned independent homes through H2 2026 and 2027.

Capacity contraction meeting demand growth. Care home bed supply per 100 people aged 75+ fell from 11.3 in 2012 to 9.3 in 2023, a 17.7% decline confirmed by the Nuffield Trust. The 75+ population continues to grow. Demand for well-rated capacity is structurally underpinned.

Welltower-driven consolidation cycle. The £6 billion+ Welltower transactions are the largest single capital event in UK care home history. The phase 2 CMA process and likely undertakings create a 12 to 18 month window of structured divestment opportunities, regional defensive acquisition activity, and elevated competitive pressure on independent sellers' assets.

Self-funder fee growth. Self-funder weekly fees have outpaced inflation in most regions through 2024-2026, with London nursing care averages now at £1,759 per week and South East nursing care at £1,706. Operators with majority-self-funder homes are seeing real-terms revenue growth flow directly to EBITDA. This translates into multiple expansion when those operators come to market.

The same PE-driven consolidation thesis driving these dynamics is visible across UK building services M&A, where capital concentration into specialist platforms accelerates wherever regulatory or operational scale benefits exist.

What can go wrong: the diligence items that derail care home deals

Three issues account for the majority of UK care home transactions that fall over in due diligence.

Hidden CQC compliance issues. Buyers now request the full inspection history, internal action plans, safeguarding logs and complaint records. Material undisclosed enforcement notices, conditional registrations or pattern complaints typically result in either re-negotiation at material discount or deal abandonment. Disclose proactively in the information memorandum.

Property and lease structure complexity. Mixed freehold/leasehold portfolios, related-party leases, mortgage encumbrances and historical planning issues all delay completion and erode buyer confidence. Conduct a property and title audit before going to market.

Working capital and net debt manipulation. UK care home SPAs almost universally adjust for working capital normalisation, prepaid resident fees treatment, and accrued staff costs. Sellers without a properly modelled working capital position routinely concede 5% to 10% of headline value at completion. Engage advisors who can model the working capital target with rigour.

Preparing for sale: the 12-month roadmap

For owners targeting an exit in 2027, work backwards from the target completion date.

Month 1-3: Diagnostic and positioning. Independent EBITDA quality assessment, CQC evidence audit, property and title review, working capital baseline, fee mix analysis. Month 4-6: Value enhancement. Address remediable CQC items, optimise staffing model, document quality systems, prepare digital evidence files. Month 7-9: Buyer mapping and information memorandum. Identify the 30 to 60 most likely buyers, prepare the confidential information memorandum, build the financial dataroom. Month 10-12: Process launch and execution. Outreach, NDA management, indicative offers, management presentations, final bids, SPA negotiation, completion.

Owners who skip the preparation phase and engage buyers directly typically realise 15% to 25% less cash at completion than equivalent operators who run a structured advisory-led process.

How DealFlowAgent supports care home owners

DealFlowAgent is a specialist M&A advisory for UK care home owners. Our team maintains live transaction comparables across CQC rating, region, freehold status and bed count; runs structured competitive processes targeting the full named UK and international buyer universe; models working capital, net debt and earn-out mechanics to maximise cash at completion; and provides the regulatory positioning advice that has become essential in the post-Welltower, post-SAF transition environment.

If you operate one or more UK care homes valued between £1 million and £30 million and you are considering exit in the next 24 months, book a confidential call with our advisory team. Every conversation is confidential. We provide an indicative valuation range, named buyer mapping and a process recommendation within the first meeting.

Your Advisory Team

Experienced Dealmakers Lead Your Exit

Every exit is led by a senior advisor who has been through it themselves. Meet the team who will guide you.

Joe Lewin

Founder & Lead Advisor — M&A Specialist

• •4 years in M&A advisory; 22 completed transactions
• •Direct relationships with hundreds of strategic and financial acquirers
• •Raised £2m in funding; placed 3rd of 1,900 at OnStage (the "Y Combinator of Europe")
• •Previously built a mobility and field services business to 30 staff and 6 UK warehouses, then sold via competitive process with an EY M&A partner
• •Full-stack developer of advanced agent systems and second-brain tooling for the M&A process

Joe Thomason

Senior M&A Advisor

• •Previously Analyst at KBS Corporate
• •Analyst at Hampleton Partners, Associate at Tech Credit Partners
• •Worked on 25+ completed transactions (£300k to £120m)
• •Specialist in debt lending for business buyers

Emerson Patton

Sector Specialist: Building, Construction & Trade Services

• •20+ years advising owners in building services, fire safety, HVAC, plumbing, and construction
• •Guided 200+ companies through growth, profit improvement, and exit planning
• •Builds equity value and operational structure long before a sale
• •Partners with DFA to prepare owners for exit while the advisory team runs the sale

Sam Pouyan

Senior M&A Advisor

• •10 years across buy-side and sell-side M&A
• •Former investment banking analyst
• •Expert in financial modelling and deal structuring

James Duboullay

Senior M&A Advisor

• •25+ years across investment banking, M&A and fundraising
• •Sector focus: essential services and software
• •Long-standing relationships with private equity buyers and growth funds
• •Personally advising DealFlowAgent founders for the past four years

Sage

AI Deal Concierge

• •Available 24/7. Monitors every signal in your deal
• •Keeps your advisory team one step ahead at all times
• •Trained on thousands of M&A transactions

Sterling

Buy-Side Deal Origination Agent

• •Engages 12,000+ acquirers to surface live mandates and intent
• •Qualifies buyer fit, budget and timing before introductions
• •Feeds your advisory team with warm, ranked buyer matches

Tim Armoo

Partner & Chief Marketing Officer

• •Founded Fanbytes, scaled revenues to £10m+, exited at multi-eight-figure valuation
• •Advises on multiple M&A deals, invests in early-stage ventures
• •Built 700,000+ follower community teaching founders to scale and sell
• •Partnered with DealFlowAgent to expand access for founders to buyers

Assigned Per Deal

Sector Expert

Industry-Specific M&A Advisor

For every deal, our advisory team includes a sector specialist from that client's specific industry and niche: bringing relationships, insider knowledge, and leverage to support your process and achieve the best acquisition outcome.

INTERVIEWING

Head of M&A

Senior hire — interviewing now

Final-round interviews underway with 100+ applicants. Joining May 2026 to lead the advisory bench across Building Services and Healthcare.

OFFER STAGE

Senior M&A Advisor

New seat — 100+ applicants

Sourced from boutique investment banks and Big-4 corporate finance teams. Joining May–June 2026.

INTERVIEWING

Senior M&A Advisor

Second seat — interviewing

Sector-specialist hire focused on the lower-mid market (£1M–£10M EBITDA). Joining May–June 2026.

We're actively expanding the bench — three senior M&A hires confirmed for May–June 2026. See open roles → Apply now →

Healthcare M&A Specialists

Thinking of selling your healthcare business?

DealFlowAgent is the UK and US's only M&A advisory firm specialising in healthcare businesses. Our trusted advisors leverage industry knowledge, buyer relationships and proprietary technology to help business owners secure multiple acquisition offers at higher valuations.

Talk to a Real Advisor - No Obligation

Speak with Joe or Sam about your situation. No hard sell, no commitment, just honest advice from advisors who've been through it.

What's Your Business Actually Worth?

Our valuation tool gives you a realistic range based on recent comparable transactions in your sector. Takes 3 minutes.

Related Articles